


**Product Name** : AZD8186  
**Cat. No.** : PC-42978  
**CAS No.** : 1627494-13-6  
**Molecular Formula** : C<sub>24</sub>H<sub>25</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub>  
**Molecular Weight** : 457.4698  
**Target** : PI3K  
**Solubility** : DMSO: ≥ 35 mg/mL



## Biological Activity

AZD8186 is a potent, isoform-specific **PI3K $\beta$**  inhibitor with IC<sub>50</sub> of 4 nM, also inhibits PI3K $\delta$  (IC<sub>50</sub>=12 nM) with selectivity over PI3K $\alpha$  (IC<sub>50</sub>=35 nM) and PI3K $\gamma$  (IC<sub>50</sub>=675 nM).

AZD8186 inhibits ADP-induced human platelet aggregation with IC<sub>50</sub> of 186 nM, shows no significant binding to 442 other kinases.

AZD8186 inhibits PI3K $\beta$ -dependent activation of pAKT (Ser473) in MDA-MB-468 cells (IC<sub>50</sub>=3 nM), inhibits proliferation of MDA-MB-468 cells (GI<sub>50</sub>=65 nM).

AZD8186 suppresses phosphorylation of AKT, PRAS40, S6, and FOXO with IC<sub>50</sub> of <10-300 nM in breast cancer cells, also induces nuclear translocation of FOXO3a in vitro.

AZD8186 effectively inhibits growth of prostate and TNBC tumors, both as a single agent and in combination with docetaxel.

## References

Hancox U, et al. *Mol Cancer Ther.* 2015 Jan;14(1):48-58.

Barlaam B, et al. *J Med Chem.* 2015 Jan 22;58(2):943-62.

Schwartz S, et al. *Cancer Cell.* 2015 Jan 12;27(1):109-22.

Lynch JT, et al. *Clin Cancer Res.* 2017 Dec 15;23(24):7584-7595.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com